Want to see MIRM full AI Analyst Report?
MIRM Stock Chart & Stats
$98.08
-$1.33(-1.16%)
At close: 4:00 PM EDT
$98.08
-$1.33(-1.16%)
Day’s Range― - ―
52-Week Range$63.23 - $130.00
Previous CloseN/A
Volume516.94K
Average Volume (3M)817.95K
Market Cap
$5.34B
Enterprise Value$7.74B
Total Cash (Recent Filing)$438.29M
Total Debt (Recent Filing)$760.54M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Nov 17, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.56
Shares Outstanding64,932,205
10 Day Avg. Volume896,957
30 Day Avg. Volume817,952
Financial Highlights & Ratios
PEG Ratio2.25
Price to Book (P/B)12.60
Price to Sales (P/S)7.61
P/FCF Ratio72.26
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue12.53
Enterprise Value/Gross Profit15.34
Enterprise Value/Ebitda-9.97
Forecast
1Y Price Target
$154.45Price Target Upside57.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-15.12
Revenue Forecast (FY)$698.10M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthStrong quarterly sales growth and raised full-year guidance indicate sustained demand for Mirum’s marketed rare-disease portfolio. Continued expansion across Livmarli and bile-acid medicines can support increasing commercial scale, reinforce operating leverage, and provide a durable revenue base over the next several quarters.
LIVMARLI Label ExpansionThe positive EXPAND Phase 3 results strengthen the evidence base for LIVMARLI in additional ultra-rare cholestatic diseases, including biliary atresia. A supplemental filing could broaden the label, increase the eligible patient population, and deepen the product’s competitive position in an established specialty market.
Pipeline DiversificationU.S. approval of Atebrioz adds a commercial product beyond Mirum’s liver portfolio, while AZURE-1 success advances a potentially significant hepatitis delta opportunity. These developments diversify future revenue sources and reduce reliance on the current products, provided launches and subsequent regulatory steps execute successfully.
Bears Say
Profitability And Cash BurnThe latest trailing period shows a sharp deterioration from prior positive cash generation, with substantial operating losses and renewed free-cash-flow burn. This weakens internal funding capacity, increases dependence on external capital, and may constrain Mirum’s ability to fund its broad development and commercialization plans without further financing.
Balance-Sheet StressHigher debt combined with negative equity materially reduces financial flexibility and increases reliance on successful operating performance or capital-market access. The weaker capital structure can limit discretionary investment, raise financing risk, and make it harder to absorb setbacks in clinical development or product launches.
PSC Regulatory DelayThe FDA’s request for an additional Phase 3 study delays potential PSC approval and associated commercialization revenue beyond the company’s earlier timetable. The change adds development cost and execution uncertainty, while requiring further regulatory alignment before Mirum can convert encouraging clinical results into a marketed indication.
Mirum Pharmaceuticals News
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $63.23 and its highest was $130.00 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Mirum Pharmaceuticals Inc’s market cap is $5.34B.
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 17, 2026 which is in 27 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Aug 05, 2026. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.317.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -0.49.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 64,932,205 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -11.036%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MIRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirum Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$154.45 (57.48% Upside)
$154.45 (57.48% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 172.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.48%
12-Months-Change
Fundamentals
Return on Equity
-410.20%
Trailing 12-Months
Asset Growth
43.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
MIRM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial execution (Q2 sales up 37.5% YoY), improved margins (+~5 percentage points) a fortified balance sheet (cash up ~43.5%, successful convertible note financing), and multiple near-term clinical and regulatory catalysts (Zilurgisertib PDUFA, volovitug/volixibat and volovitug AZURE readouts). The most significant negative item is regulatory uncertainty for volixibat in PSC after the FDA recommended a Phase 3, leading to an NDA timing delay to H1 2027 and added execution risk. Overall, positive commercial and financial momentum and multiple upcoming catalysts outweigh the regulatory setback, but the PSC pathway remains a material watch item.View all MIRM earnings summariesMIRM Stock 12 Month Forecast
Average Price Target
$154.45
▲(57.48% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
PTC Therapeutics
―
Viking Therapeutics
―
Ownership Overview
7.53% Insiders
28.08% Mutual Funds
0.17% Other Institutional Investors
49.27% Public Companies and
Individual Investors